Pasireotide Exerts Anti-Inflammatory Effects in the Endothelium

Growth hormone (GH) modulates normal growth and metabolism, and its effects are counteracted by somatostatin (SST). Pasireotide (PAS), an FDA-approved synthetic derivative of somatostatin, acts via binding to multiple somatostatin receptors, and it is commonly used in conditions unresponsive to first-generation somatostatin analogs. Herein we explore the potential of PAS to protect against endothelial dysfunction induced by lipopolysaccharides (LPS). This is a bacterial toxin which causes inflammation and compromises endothelial barrier integrity. Endothelial cells were treated with PAS before LPS exposure to evaluate the corresponding effects on cell viability, inflammation, and barrier function. Since PAS suppressed LPS-triggered endothelial injury, it is suggested that this compound could be repurposed for endothelium-dependent disorder treatment.